In recent years, studies have shown that triggering the antitumor immunity of CD8+ T cells in the tumor microenvironment (TME) by immunotherapy brings prominent and long-lasting clinical benefits for NSCLC [2]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.